Health Care & Life Sciences » Pharmaceuticals | Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
27.19 M
Public Float
21.59 M
Adamas Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$4.61
Market Cap
$165.2 M
Shares Outstanding
27.53 M
Public Float
21.89 M

Profile

Address
1900 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.adamaspharma.com
Updated 07/08/2019
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease.

Financials

View All
Created with Highcharts 5.0.14Adamas Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.34 50434 5049 4009 40051 80251 80260 05860 05889 49089 490130 999130 999201320142015201620172018025k50k75k100k125k150k
Created with Highcharts 5.0.14Adamas Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.71 09571 09555 84655 8461 9161 91657257257157134 04634 046201320142015201620172018020k40k60k80k

Gregory T. Went
Chairman & Chief Executive Officer
Mardi C. Dier
Director